Business Wire

MI-EATON

14.7.2020 23:39:14 CEST | Business Wire | Press release

Share
Eaton’s Vehicle Group Leveraging Industry 4.0 Technology to Navigate COVID-19 Pandemic

Power management company Eaton today announced its Vehicle Group has been leveraging advanced Industry 4.0 technology to help its global operations safely navigate the ongoing COVID-19 crisis and continue to service its customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714006047/en/

Eaton’s Vehicle Group envisions Industry 4.0 as both operational and informational technologies, enabling autonomous production systems that are connected, optimized, transparent, proactive, and agile. Supported by an integrated ecosystem, the technologies are composed of augmented reality, rapid application development, autonomous robots, digital simulation, and additive manufacturing.

“I’m proud of our Vehicle Group team and their ingenuity, especially during the COVID-19 pandemic,” said João Faria, president, Vehicle Group. “By leveraging augmented reality, we are able to continue to support our operations remotely and continue the development of new products, ensuring our customer deadlines are met despite the global challenges we are all facing.”

Here are examples of how the Vehicle Group is using Industry 4.0 technologies:

Displaying 3D images and connecting remotely to improve safety

To enable remote assistance and critical activities, Vehicle Group teams are using Microsoft’s HoloLens 2 augmented reality goggles that offer the capability to display 3D images in physical spaces and connect remotely. This remote assistance technology ensures that ongoing work can be performed while keeping everyone safe.

Enhancing training and expediting review processes through augmented reality

Augmented reality also assists with knowledge retention and ongoing training. For instance, the Vehicle Group identified an opportunity to use the technology to train operators and engineers on new equipment, which would have traditionally been conducted by instructors who travel to the various remote sites. Additionally, the technology has proven critical for recent customer reviews and approvals.

Analyzing data to reduce costs, improve quality and reduce lead times

Eaton’s Vehicle Group is interconnecting plant systems and machines to collect, analyze and report real-time information, which optimizes plant floor management and provides visibility to real-time production issues in order to address them right away. These efforts are designed to reduce lead times; maintenance, repair and operations (MRO), inventory, indirect-labor/direct-labor costs; as well as increase performance and improve quality.

Implementing robots to promote safe distancing and increase productivity

To optimize manufacturing flow and eliminate the need for forklifts and other human-operated transport machinery, the Vehicle Group is using autonomous automated guided vehicles (AGVs) or autonomous mobile robots (AMRs). In addition to improving the flow of materials throughout a manufacturing facility, AMRs and autonomous AGVs increase safety and allow for social distancing while also lowering costs.

COBOTs, which are robots intended to interact with humans in a shared space or to work safely in close proximity, are being used to safely handle complex and repetitive tasks. This results in improved consistency and accuracy during the manufacturing process.

Using digital simulation to improve production efficiency

Another way the Vehicle Group is increasing productivity is by using digital simulation applications to define which solution and/or combination of factors will result in the highest output. These applications can run several scenarios by changing parameters, such as the number of operators, work in process material, cycle times, operator standardized work and many others. The applications are being used to define new manufacturing cells and assembly lines or to redesign existing ones. In most cases, the Vehicle Group is seeing productivity increase from 10 to 30 percent via higher production output or reduced amount of investment needed.

Leveraging 3D printing tools internally to expedite processes

Additive manufacturing is leveraged to improve safety, quality and efficiency by designing and producing tools, poke-yokes and gauges internally on both polymer and metal materials. This allows fast reactions (shorter lead times), reduced purchase costs and highly customized solutions. For example, lead times can be reduced from weeks to days, while reducing costs from thousands to hundreds.

Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2019 revenues were $21.4 billion, and we sell products to customers in more than 175 countries. We have approximately 95,000 employees. For more information, visit www.eaton.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye